ATE307608T1 - Kombination von doctaxel und rhumab her2 zür krebsbehandlung - Google Patents

Kombination von doctaxel und rhumab her2 zür krebsbehandlung

Info

Publication number
ATE307608T1
ATE307608T1 AT00923156T AT00923156T ATE307608T1 AT E307608 T1 ATE307608 T1 AT E307608T1 AT 00923156 T AT00923156 T AT 00923156T AT 00923156 T AT00923156 T AT 00923156T AT E307608 T1 ATE307608 T1 AT E307608T1
Authority
AT
Austria
Prior art keywords
rhumab her2
doctaxel
combination
cancer treatment
docetaxel
Prior art date
Application number
AT00923156T
Other languages
English (en)
Inventor
Charles Le Vogel
Robert E Bellet
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22435924&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE307608(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE307608T1 publication Critical patent/ATE307608T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Drying Of Gases (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
AT00923156T 1999-04-09 2000-04-07 Kombination von doctaxel und rhumab her2 zür krebsbehandlung ATE307608T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12856499P 1999-04-09 1999-04-09
PCT/US2000/009247 WO2000061185A1 (en) 1999-04-09 2000-04-07 Docetaxel in combination with rhumab her2 for the treatment of cancers

Publications (1)

Publication Number Publication Date
ATE307608T1 true ATE307608T1 (de) 2005-11-15

Family

ID=22435924

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00923156T ATE307608T1 (de) 1999-04-09 2000-04-07 Kombination von doctaxel und rhumab her2 zür krebsbehandlung

Country Status (22)

Country Link
US (1) US6333348B1 (de)
EP (1) EP1169059B1 (de)
JP (2) JP2003512298A (de)
KR (1) KR100695383B1 (de)
CN (1) CN1191859C (de)
AT (1) ATE307608T1 (de)
AU (1) AU777661B2 (de)
BR (1) BR0009647A (de)
CA (1) CA2368369C (de)
CZ (1) CZ296373B6 (de)
DE (1) DE60023476T2 (de)
DK (1) DK1169059T3 (de)
EA (1) EA006097B1 (de)
ES (1) ES2248070T3 (de)
HK (2) HK1043313A1 (de)
HU (1) HU226672B1 (de)
MX (1) MXPA01010138A (de)
NO (1) NO332619B1 (de)
NZ (1) NZ515337A (de)
TR (1) TR200102845T2 (de)
WO (1) WO2000061185A1 (de)
ZA (1) ZA200107771B (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
BR9912053A (pt) * 1998-07-13 2001-04-03 Univ Texas Processos de tratamento de câncer utilizando conjugados terapêuticos que se ligam a aminofosfolipìdios
US6818213B1 (en) * 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
US6406693B1 (en) * 1998-07-13 2002-06-18 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
EP1096955B9 (de) 1998-07-13 2006-07-05 Board of Regents, The University of Texas System Verwendung von antikörper gegen aminophospholipide zur krebsbehandlung
US6333348B1 (en) * 1999-04-09 2001-12-25 Aventis Pharma S.A. Use of docetaxel for treating cancers
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
DE60033658T2 (de) * 1999-06-25 2007-11-22 Genentech, Inc., South San Francisco Behandlung von prostata-krebs mit anti-erbb2 antikörpern
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
GB9917012D0 (en) * 1999-07-20 1999-09-22 Pharmacia & Upjohn Spa Combined preparations comprising antitumor agents
EP2110138A1 (de) * 1999-08-27 2009-10-21 Genentech, Inc. Dosierungen zur Behandlung von Anti-erbB2-Antikörpern
WO2001089566A1 (en) * 2000-05-19 2001-11-29 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
AU2002232413A1 (en) * 2000-11-21 2002-06-03 Cell Pathways, Inc. Method for treating neoplasia by administering an anti-her2 antibody and a cgmp-specific phosphodiesterase inhibitor
US7141576B2 (en) * 2001-01-16 2006-11-28 Smithkline Beecham (Cork) Limited Cancer treatment method
CN1551767A (zh) 2001-02-19 2004-12-01 ��˹��ŵ�� 癌症的治疗
WO2002087629A1 (en) * 2001-04-26 2002-11-07 Analogic Corporation Ct scanner for imaging a preselected portion of a patient
AU2002351353A1 (en) * 2001-12-19 2003-09-02 Genentech, Inc. Stabilizing polypeptides which have been exposed to urea
GB0200657D0 (en) * 2002-01-12 2002-02-27 Antisoma Plc Cancer treatment
DE60335383D1 (de) * 2002-07-15 2011-01-27 Univ Texas Antikörper mit bindung an anionische phospholipide und aminophospholipide und ihre verwendung bei der behandlung von virusinfektionen
US7678386B2 (en) 2002-07-15 2010-03-16 Board Of Regents The University Of Texas Liposomes coated with selected antibodies that bind to aminophospholipids
US7622118B2 (en) * 2002-07-15 2009-11-24 Board Of Regents, The University Of Texas System Cancer treatment methods using selected antibodies to aminophospholipids
US7714109B2 (en) * 2002-07-15 2010-05-11 Board Of Regents, The University Of Texas System Combinations and kits for cancer treatment using selected antibodies to aminophospholipids
US7247303B2 (en) * 2002-07-15 2007-07-24 Board Of Regents, The University Of Texas System Selected antibody CDRs for binding to aminophospholipids
US7615223B2 (en) * 2002-07-15 2009-11-10 Board Of Regents, The University Of Texas System Selected immunoconjugates for binding to aminophospholipids
US7572448B2 (en) * 2002-07-15 2009-08-11 Board Of Regents, The University Of Texas System Combined cancer treatment methods using selected antibodies to aminophospholipids
US7625563B2 (en) * 2002-07-15 2009-12-01 Board Of Regents, The University Of Texas System Cancer treatment methods using selected immunoconjugates for binding to aminophospholipids
EP1572972A4 (de) * 2002-11-21 2007-11-21 Genentech Inc Therapie nichtmaligner krankheiten oder störungen mit anti-erbb2-antikörpern
US7989490B2 (en) 2004-06-02 2011-08-02 Cordis Corporation Injectable formulations of taxanes for cad treatment
EP3698807A1 (de) 2005-01-21 2020-08-26 Genentech, Inc. Fixe dosierung von her-antikörpern
WO2006086730A2 (en) * 2005-02-09 2006-08-17 Genentech, Inc. Inhibiting her2 shedding with matrix metalloprotease antagonists
RS53128B (sr) 2005-02-23 2014-06-30 Genentech Inc. Produžavanje vremena progresije bolesti ili preživljavanja kod pacijenata obolelih od kancera jajnika korišćenjem pertuzumaba
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
US20070172844A1 (en) * 2005-09-28 2007-07-26 University Of South Florida Individualized cancer treatments
EP1913958B1 (de) * 2006-08-03 2009-12-23 Sanofi-Aventis Antitumorale Zusammensetzungen enthaltend Acetylcyclopropyl Docetaxel und Trastuzumab
FR2904782B1 (fr) * 2006-08-11 2008-10-31 Delta Proteomics Soc Par Actio Co-colloides supramoleculaires obtenus a l'aide de systemes macrocycliques polyanioniques
MX2009008981A (es) 2007-03-02 2009-09-02 Genentech Inc Prediccion de respuesta a un inhibidor her.
WO2008154249A2 (en) 2007-06-08 2008-12-18 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
EP2133433A1 (de) * 2008-06-09 2009-12-16 Centre Georges François Leclerc Verfahren zur Vorhersage der Reaktion auf eine Behandlung mit einem Antikörper gegen HER2
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
EP2358199A2 (de) * 2008-11-02 2011-08-24 Optimata Ltd. Verbesserung der krebs-therapie durch docetaxel und des granulozyt-colony stimulierungsfaktor (g-csf)
MD36Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului ductal in situ neinvaziv al glandei mamare
MD23Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului lobular in situ neinvaziv al glandei mamare
MD24Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului neinvaziv al glandei mamare
MD35Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de apreciere a riscului dezvoltării carcinomului neinvaziv in situ al glandei mamare
KR20150036824A (ko) 2009-03-20 2015-04-07 제넨테크, 인크. 이중특이적 항-ｈｅｒ 항체
US20120121586A1 (en) 2009-05-29 2012-05-17 Astrid Kiermaier Modulators for her2 signaling in her2 expressing patients with gastric cancer
ES2519348T3 (es) 2010-02-18 2014-11-06 Genentech, Inc. Antagonistas de neurregulina y uso de los mismos en el tratamiento del cáncer
WO2011139172A1 (en) 2010-05-06 2011-11-10 Goran Milosavljevic Diterpene compounds with antineoplastic activities and pharmaceutical compositions comprising same
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
WO2012069466A1 (en) 2010-11-24 2012-05-31 Novartis Ag Multispecific molecules
EP2655413B1 (de) 2010-12-23 2019-01-16 F.Hoffmann-La Roche Ag Polypeptid-polynukleotid-komplex und verwendung bei der gezielten effektorrest-bereitstellung
BR112014003431A2 (pt) 2011-08-17 2017-06-13 Genentech Inc anticorpo, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, agente farmacêutico, uso do anticorpo, método de tratamento de um indivíduo que tem câncer e método de aumento de tempo para recorrência de tumor
SG11201400208PA (en) * 2011-09-01 2014-03-28 Vascular Biogenics Ltd Formulations and dosage forms of oxidized phospholipids
CN102321175B (zh) * 2011-09-21 2013-08-07 天津胜发生物技术有限公司 针对乳腺癌Her2/new的纳米抗体或多肽
WO2013063229A1 (en) 2011-10-25 2013-05-02 The Regents Of The University Of Michigan Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
AU2012346540C1 (en) 2011-11-30 2019-07-04 Genentech, Inc. ErbB3 mutations in cancer
WO2013083810A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
WO2013148315A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
US9308235B2 (en) 2012-05-09 2016-04-12 Spectrum Pharmaceuticals, Inc. Treatment of primary and metastatic carcinoma
RU2692773C2 (ru) 2012-11-30 2019-06-27 Ф.Хоффманн-Ля Рош Аг Идентификация пациентов, нуждающихся в совместной терапии с использованием ингибитора pd-l1
CN103102414B (zh) * 2013-02-04 2014-08-27 无锡傲锐东源生物科技有限公司 抗her2蛋白单克隆抗体及其用途
US20190151346A1 (en) 2016-05-10 2019-05-23 INSERM (Institute National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
CN109966499A (zh) * 2019-04-25 2019-07-05 苏州大学 协同增效的抗乳腺癌转移药物组合物及其用途
IL311003A (en) 2021-08-25 2024-04-01 Denali Therapeutics Inc Anti-2HER antibodies and methods of using them

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US6333348B1 (en) * 1999-04-09 2001-12-25 Aventis Pharma S.A. Use of docetaxel for treating cancers

Also Published As

Publication number Publication date
EP1169059B1 (de) 2005-10-26
MXPA01010138A (es) 2003-07-14
CN1191859C (zh) 2005-03-09
DE60023476T2 (de) 2006-07-06
ES2248070T3 (es) 2006-03-16
AU4332700A (en) 2000-11-14
DK1169059T3 (da) 2006-02-27
NZ515337A (en) 2003-10-31
AU777661B2 (en) 2004-10-28
JP2012136535A (ja) 2012-07-19
EA200101064A1 (ru) 2002-04-25
EP1169059A1 (de) 2002-01-09
CN1350464A (zh) 2002-05-22
HK1046093A1 (en) 2002-12-27
HK1043313A1 (zh) 2002-09-13
CZ296373B6 (cs) 2006-03-15
US6333348B1 (en) 2001-12-25
HUP0201459A3 (en) 2003-04-28
KR20020007358A (ko) 2002-01-26
DE60023476D1 (de) 2005-12-01
CA2368369A1 (en) 2000-10-19
HK1046093B (zh) 2005-10-28
KR100695383B1 (ko) 2007-03-15
ZA200107771B (en) 2002-09-20
NO332619B1 (no) 2012-11-19
NO20014842L (no) 2001-10-04
EA006097B1 (ru) 2005-08-25
TR200102845T2 (tr) 2002-01-21
CA2368369C (en) 2014-03-25
WO2000061185A1 (en) 2000-10-19
CZ20013614A3 (cs) 2002-07-17
BR0009647A (pt) 2002-01-08
JP2003512298A (ja) 2003-04-02
HU226672B1 (en) 2009-06-29
HUP0201459A2 (en) 2002-09-28
NO20014842D0 (no) 2001-10-04

Similar Documents

Publication Publication Date Title
DE60023476D1 (de) Kombination von doctaxel und rhumab her2 zür krebsbehandlung
TW200518752A (en) Combinations of drugs for the treatment of neoplasms
WO2004062604A3 (en) Treatment of cancer with 2-deoxyglucose
MXPA03010121A (es) Terapia de combinacion que utiliza anticuerpos anti-receptor de factor de crecimiento epidermico y agentes anti-hormonales.
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
YU13603A (sh) Postupci tretiranja poremećaja povenzanih sa bcl-2 primenom bcl-2 antisens oligomera
DK1289517T3 (da) Farmaceutiske sammensætninger indeholdende cannabidiolderivater
WO2004006842A3 (en) Combinations of drugs for the treatment of neoplasms
BR0213906A (pt) Métodos para a produção de um efeito anti-angiogênico e ou redutor da permeabilidade vascular em um animal de sangue quente, e para o tratamento de um câncer em um animal de sangue quente, composição farmacêutica, kit, e, uso de zd6474 ou um seu sal farmaceuticamente aceitável e um taxano
MY146533A (en) Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer
AR050418A1 (es) Dosificacion fija de anticuerpos her
ES2123642T3 (es) Metodo para el tratamiento del cancer por terapia conjunta con derivados de 2'-halometilideno y un agente antineoplasico especifico de fase s o fase m.
BR9813318A (pt) Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
UA32457C2 (uk) Лікарський засіб (варіанти) і спосіб медикаментозного впливу на організм
DE602004016376D1 (de) Kombination von et-743 mit 5-fluorouracil pro-drugs zur behandlung von krebs
DE60222383D1 (de) Medikament zur verabreichung von amifostin und verwandten wirkstoffen
MXPA04001912A (es) Aminobenzofenonas novedosas.
WO2004056971A3 (en) Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
BRPI0404050A (pt) Uso de um composto ou de um seu sal ou éster farmaceuticamente aceitável, formulação farmacêutica, formulação acondicionada, composto, e, método para prevenir e/ou tratar hiperplasia benigna da próstata em pacientes em necessidade de tal prevenção ou tratamento
ATE345805T1 (de) Calciumtrifluoracetat mit zytotoxischer wirkung
WO2002076393A3 (en) Antiagionecic, antitumor, chemopreventative agents
RU2003124971A (ru) Способ лечения больных с невротическими и соматоформными расстройствами
DK1150981T3 (da) Terapeutisk necleosidforbindelse
FI20010233A0 (fi) Menetelmä sydämen vajaatoiminnan hoitoon
DE60125377D1 (de) Behandlung von hepatitis c mit thymosin, interferon und ribavirin

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1169059

Country of ref document: EP